The importance of antimicrobial resistance in medical mycology

Neil A. R. Gow (), Carolyn Johnson (), Judith Berman, Alix T. Coste, Christina A. Cuomo, David S. Perlin, Tihana Bicanic, Thomas S. Harrison, Nathan Wiederhold, Mike Bromley, Tom Chiller and Keegan Edgar
Additional contact information
Neil A. R. Gow: University of Exeter, Geoffrey Pope Building
Carolyn Johnson: Medical Research Council, Polaris House
Judith Berman: Tel Aviv University
Alix T. Coste: University Hospital Lausanne
Christina A. Cuomo: (CAC) Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard
David S. Perlin: Hackensack Meridian health
Tihana Bicanic: St George’s University of London
Thomas S. Harrison: University of Exeter, Geoffrey Pope Building
Nathan Wiederhold: University of Texas Health Science Center at San Antonio
Mike Bromley: University of Manchester, CTF Building
Tom Chiller: Center for Disease Control and Prevention Mycotic Disease Branch 1600 Clifton Rd, MSC-09
Keegan Edgar: Center for Disease Control and Prevention Mycotic Disease Branch 1600 Clifton Rd, MSC-09

Nature Communications, 2022, vol. 13, issue 1, 1-12

Abstract: Abstract Prior to the SARS-CoV-2 pandemic, antibiotic resistance was listed as the major global health care priority. Some analyses, including the O’Neill report, have predicted that deaths due to drug-resistant bacterial infections may eclipse the total number of cancer deaths by 2050. Although fungal infections remain in the shadow of public awareness, total attributable annual deaths are similar to, or exceeds, global mortalities due to malaria, tuberculosis or HIV. The impact of fungal infections has been exacerbated by the steady rise of antifungal drug resistant strains and species which reflects the widespread use of antifungals for prophylaxis and therapy, and in the case of azole resistance in Aspergillus, has been linked to the widespread agricultural use of antifungals. This review, based on a workshop hosted by the Medical Research Council and the University of Exeter, illuminates the problem of antifungal resistance and suggests how this growing threat might be mitigated.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-32249-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32249-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-32249-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().